PCOS: Symptoms, Diagnosis, Metabolic Risks and Evidence-Based Fertility Treatment

Evidence reviewed: 8 November 2026. Polycystic ovary syndrome (PCOS) is a common hormonal and metabolic condition associated with irregular ovulation, androgen excess and sometimes changes in ovarian morphology. Symptoms may include infrequent periods, acne, excess facial or body hair, scalp hair thinning and difficulty conceiving. PCOS is also associated with insulin resistance, increased diabetes risk and psychological distress. It should not be diagnosed solely because ultrasound shows “cysts.” The 2023 International Evidence-Based PCOS Guideline substantially updated diagnosis and treatment, including use of anti-Müllerian hormone (AMH) in selected adults and letrozole as first-line ovulation-induction medicine for appropriate anovulatory infertility [1–3].

What causes PCOS?

PCOS results from interacting genetic, reproductive and metabolic factors. In many patients, increased androgen production from ovarian cells contributes to acne, excess terminal hair growth and disrupted follicular maturation. Insulin resistance and compensatory hyperinsulinemia can amplify ovarian androgen production and lower SHBG, increasing biologically active testosterone [1,2].

PCOS does not require obesity; it occurs across body sizes and ethnic groups. Nor is it caused by poor hygiene, a single food or failure to exercise. A history of irregular menstrual cycles is important, but not every irregular period means PCOS.

Common symptoms and signs

  • Infrequent or irregular periods caused by oligo-ovulation or anovulation.
  • Hirsutism: increased coarse hair growth in androgen-sensitive areas, such as the chin, upper lip, chest or abdomen.
  • Acne or androgen-related scalp hair loss, though neither alone establishes PCOS.
  • Difficulty conceiving due to irregular or absent ovulation.
  • Weight gain or difficulty with weight management in some patients, but not everyone.
  • Metabolic concerns: insulin resistance, dyslipidemia or impaired glucose tolerance.
  • Sleep and mental-health symptoms, including increased prevalence of depression, anxiety or obstructive sleep apnea in selected groups.

Some patients have relatively regular bleeding but still meet diagnostic criteria. Others have irregular bleeding for entirely different reasons, including thyroid disease, hyperprolactinemia, pregnancy, hypothalamic dysfunction or medication effects [1,2].

How is PCOS diagnosed in adults?

The 2023 international guideline continues to use the modified Rotterdam framework: after exclusion of other causes, adults generally need two of three features [1]:

  1. Clinical or biochemical hyperandrogenism—for example hirsutism or elevated appropriate androgen tests.
  2. Irregular ovulation or menstrual cycles consistent with ovulatory dysfunction.
  3. Polycystic ovarian morphology on appropriately performed ultrasound or AMH as an alternative marker in adults, when the test is suitable.

Ultrasound or AMH is not necessary when an adult clearly has both irregular cycles and hyperandrogenism. Neither a high AMH level nor polycystic ovarian appearance alone establishes the diagnosis. AMH should not be used as a single PCOS diagnostic test or as a fertility guarantee; age, assay, hormonal contraception and other factors affect results [1].

Why are the rules different in adolescents?

Puberty commonly involves temporarily irregular cycles and multifollicular ovaries. The 2023 guideline therefore requires both persistent ovulatory dysfunction and clinical/biochemical hyperandrogenism to diagnose adolescent PCOS, after excluding alternative conditions. Ultrasound and AMH should not be used to diagnose PCOS in adolescents [1].

Some adolescents have features suggestive of PCOS but do not meet full criteria. They may be documented as “at increased risk”, offered symptom-focused care and re-evaluated as reproductive maturation progresses rather than receiving premature definitive labeling.

Which blood tests and assessments may be needed?

A clinician reviews cycle history, androgen symptoms, medications, pregnancy possibility, weight trends, blood pressure and other signs. Tests may include total and free testosterone or validated free androgen measures, with appropriate assays and careful interpretation if a person is taking combined oral contraceptives [1].

Other conditions need exclusion when relevant, such as thyroid dysfunction, elevated prolactin, non-classic congenital adrenal hyperplasia, pregnancy or Cushing syndrome. Rapidly progressive virilization, major voice deepening or very high androgen results warrants prompt specialist evaluation for rare androgen-producing tumors.

Metabolic risk: why screening is essential

PCOS is associated with increased risk of impaired glucose tolerance and type 2 diabetes, even in some people without excess weight. The 2023 guideline recommends assessment of glycemic status at diagnosis, with reassessment generally every one to three years based on additional risks. It identifies a 75-g oral glucose tolerance test (OGTT) as the most accurate available test for glycemic status in PCOS, regardless of BMI [1,2].

Also consider blood pressure, a lipid profile at diagnosis, sleep apnea symptoms and mental-health screening. Metabolic risk should be addressed respectfully, without equating PCOS with obesity or assuming every patient has diabetes.

Menstrual cycle and endometrial protection

Long periods without ovulation may expose the endometrium to unopposed estrogen, increasing risk of endometrial hyperplasia and cancer, particularly with prolonged untreated amenorrhea and other risk factors. The absolute risk of endometrial cancer remains low in young people, so routine endometrial-cancer screening is not recommended solely because PCOS is present [1].

Where pregnancy is not desired, a clinician may offer combined oral contraception for irregular cycles and androgen symptoms, a progestin-only regimen or periodic endometrial protection depending on eligibility. Unexpected persistent or heavy bleeding requires assessment. Birth control is not a cure for PCOS but can help manage important symptoms.

Managing acne and excess hair growth

Combined oral contraceptives can improve irregular cycles and hirsutism in eligible patients. Dermatologic therapies can address acne and scalp hair loss. A clinician may consider antiandrogens, such as spironolactone, when appropriate treatment has been insufficient, but effective contraception is essential during antiandrogen use because of potential fetal harm [1].

Laser or light-based hair-reduction methods may help hirsutism and quality of life. The effect varies by skin tone and hair characteristics, so experienced practitioners and realistic counseling matter. Hair growth and acne may improve over months rather than days; avoid frequent switching of treatment before an adequate trial.

Metformin: what it does and does not do

Metformin improves aspects of insulin sensitivity and metabolic risk in selected PCOS patients. The 2023 guideline recommends considering it particularly for metabolic outcomes in adults with BMI ≥25 kg/m², with individualized consideration in other patients, and also recognizes that it may improve ovulatory outcomes in selected infertility settings [1].

Metformin can cause nausea, diarrhea and other gastrointestinal symptoms, sometimes improved with gradual dose changes or extended-release preparations. Long-term use may require assessment of vitamin B12 in at-risk patients. Metformin is not the best universal first-line ovulation-induction medicine and does not automatically normalize all PCOS hormonal features [1].

PCOS infertility: begin with a full fertility assessment

Before assuming irregular ovulation is the only cause of infertility, evaluate the couple or individual fertility circumstances, including age, duration of trying, semen analysis when relevant, prior pregnancy and tubal factors. A specialist may recommend tubal-patency assessment depending on history and the intended treatment. Ovulation-inducing medicines should not be used without excluding an existing pregnancy [1].

Preconception care should address folate, blood pressure, diabetes, sleep apnea, medications and mental health. PCOS may increase risks of gestational diabetes, hypertensive disorders and other pregnancy complications; individualized monitoring can improve care [1,2].

Letrozole is the preferred first-line medicine for anovulatory infertility

The 2023 International PCOS Guideline recommends letrozole as the first-line pharmacological treatment for ovulation induction in infertile anovulatory women with PCOS and no other infertility factors [1,2].

Letrozole is an aromatase inhibitor that temporarily lowers estrogen synthesis. The resulting feedback response can increase FSH and support ovarian follicle development. Clinicians choose dosing and monitoring according to ovulation response, previous history and local practice; letrozole remains off-label for this indication in many countries. It must not be administered when pregnancy may already be present. Evidence does not show greater teratogenicity than other ovulation-induction agents when correctly used before conception, but this does not remove the need for pregnancy exclusion and careful supervision [1].

How do clomiphene and metformin compare?

Treatment Usual role Important limitations
Letrozole Preferred first-line pharmacological ovulation induction for eligible anovulatory PCOS infertility. Often off-label; assess pregnancy status and monitor ovarian response.
Clomiphene citrate Alternative ovulation-induction drug when letrozole is unavailable/unsuitable; a SERM affecting hypothalamic estrogen feedback. Risk of multiple pregnancy and ovarian overstimulation; monitoring may be needed.
Metformin May improve metabolic status and ovulatory outcomes in selected individuals; sometimes combined with clomiphene. Generally less effective than preferred ovulation agents for infertility alone.
Gonadotropin injections Usually a second-line option after oral induction failure. Requires close ultrasound/hormone monitoring because of multifollicular development and OHSS risk.
IVF Appropriate when other methods fail or other infertility factors indicate assisted reproduction. Cost, OHSS and multiple pregnancy concerns; usually prefer single embryo transfer.

The choice is not made from an arbitrary “dose–ovulation equation.” Patient-specific response and supervised monitoring are central. Clomiphene resistance does not mean that every person must proceed immediately to ovarian surgery or IVF. Other options and underlying fertility factors should be reassessed [1].

Why ovarian hyperstimulation syndrome matters

Ovarian hyperstimulation syndrome (OHSS) can occur when ovaries respond excessively to fertility stimulation. Symptoms range from abdominal discomfort to rapid abdominal swelling, persistent vomiting, shortness of breath, reduced urine output and thrombosis risk. PCOS can increase OHSS risk during gonadotropin or IVF stimulation, so clinicians use careful protocols and monitoring [1,3].

Severe abdominal distension, breathing difficulty or major illness after fertility medicines requires urgent medical evaluation. Patients should never increase ovulation-induction doses or combine fertility medicines without their fertility team.

Weight management and lifestyle: individualized, not punitive

Healthy eating, physical activity and sleep care support metabolic and mental health in all patients with PCOS. A sustainable reduction in weight may benefit selected people with excess weight, but the 2023 guideline does not identify one superior named PCOS diet, and improvements can occur with healthy behavior regardless of weight change [1].

Lean patients with PCOS still need assessment of symptoms and metabolic health. Avoid extreme calorie restriction, unproven “hormone reset” regimens, or promises that a supplement will restore ovulation reliably. Clinicians should address weight stigma and eating-disorder risk.

Frequently asked questions

Does ultrasound alone diagnose PCOS?

No. Adults need two of three accepted features after exclusion of other causes; adolescents need a stricter symptom-based approach [1].

Can AMH alone diagnose PCOS?

No. AMH may be an alternative to ultrasound in selected adults, not a stand-alone test or a diagnostic tool in adolescents [1].

Can someone with PCOS become pregnant?

Yes. Many people conceive spontaneously or with appropriate ovulation-induction treatment and fertility support.

Is clomiphene still the preferred first option?

Not for most eligible anovulatory PCOS infertility. The 2023 guideline prioritizes letrozole [1].

Does everyone with PCOS need metformin?

No. Treatment should match metabolic findings, symptoms, BMI context, fertility plans and tolerance.

Is PCOS the same as having ovarian cysts?

No. PCOS is a reproductive and metabolic syndrome, not simply enlarged ovarian cysts.

Key takeaways

PCOS requires a carefully supported diagnosis and assessment beyond fertility symptoms. Screen for metabolic and psychological concerns, manage endometrial risk, choose menstrual or androgen treatments based on goals, and recognize letrozole as preferred first-line ovulation induction for eligible anovulatory infertility.

References

  1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2023;38(9):1655–1679. doi:10.1093/humrep/dead156.
  2. American Society for Reproductive Medicine. 2023 international evidence-based PCOS guideline: recommendations.
  3. American Society for Reproductive Medicine. Clinical practice guidance for ovulation induction and assisted reproduction. Accessed 8 Nov 2026.
  4. National Institute of Diabetes and Digestive and Kidney Diseases. Polycystic ovary syndrome (PCOS). Accessed 8 Nov 2026.

Medical disclaimer: Educational information only. Hormonal treatment, fertility medicines and metabolic assessment should be individualized. Do not use letrozole, clomiphene or gonadotropins without specialist supervision or when pregnancy may already be present. Severe symptoms after ovarian stimulation require urgent care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *